Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1ALEMTUZUMAB[1] Alemtuzumab[1] D02802 (Name: Alemtuzumab)[1] CD52 💬-[17] 13, 15, 19, 20, 36, 43, 44, 46, 51, 60, 63, 65, 85, 96, 164, 283, 284
2Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994[1] Alemtuzumab[1] D02802 (Name: Alemtuzumab)[1] CD52 💬-[1] 46
3Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994)[1] Alemtuzumab[1] D02802 (Name: Alemtuzumab)[1] CD52 💬-[1] 46
4Alemtuzumab (Campath )[1] Alemtuzumab[1] D02802 (Name: Alemtuzumab)[1] CD52 💬-[1] 60
5Alemtuzumab (Campath)[1] Alemtuzumab[1] D02802 (Name: Alemtuzumab)[1] CD52 💬-[1] 15
6Alemtuzumab (GZ402673)[1] Alemtuzumab[1] D02802 (Name: Alemtuzumab)[1] CD52 💬-[1] 13
7Alemtuzumab 0.2 mg[1] Alemtuzumab[1] D02802 (Name: Alemtuzumab)[1] CD52 💬-[2] 65, 164
8Alemtuzumab 0.3 mg[1] Alemtuzumab[1] D02802 (Name: Alemtuzumab)[1] CD52 💬-[2] 65, 164
9Alemtuzumab 12 mg[1] Alemtuzumab[1] D02802 (Name: Alemtuzumab)[1] CD52 💬-[1] 13
10Alemtuzumab 24 mg[1] Alemtuzumab[1] D02802 (Name: Alemtuzumab)[1] CD52 💬-[1] 13
11Alemtuzumab and Rituximab[2] Alemtuzumab,
Rituximab		[2] D02802 (Name: Alemtuzumab),
D02994 		[2] CD52,
MS4A1 💬		[2] , Hematopoietic cell lineage 💬[1] 60
12Alemtuzumab GZ402673[1] Alemtuzumab[1] D02802 (Name: Alemtuzumab)[1] CD52 💬-[1] 13
13Alemtuzumab immunotherapy[1] Alemtuzumab[1] D02802 (Name: Alemtuzumab)[1] CD52 💬-[1] 13
14Alemtuzumab Injection[1] Alemtuzumab[1] D02802 (Name: Alemtuzumab)[1] CD52 💬-[1] 13
15Alemtuzumab Injection [Lemtrada][1] Alemtuzumab[1] D02802 (Name: Alemtuzumab)[1] CD52 💬-[1] 13
16Alemtuzumab, Rituximab[2] Alemtuzumab,
Rituximab		[2] D02802 (Name: Alemtuzumab),
D02994 		[2] CD52,
MS4A1 💬		-[1] 63
17CAMPATH-1H (Alemtuzumab)[1] Alemtuzumab[1] D02802 (Name: Alemtuzumab)[1] CD52 💬-[1] 60
18Filgrastim, Alemtuzumab[2] Alemtuzumab,
Filgrastim		[2] D02802 (Name: Alemtuzumab),
D03235 		[2] CD52,
CSF3R 💬		[6] , Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬[1] 65
19Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab[12] Acetate,
Alemtuzumab,
Cladribine,
Dimethyl fumarate,
Fingolimod,
Glatiramer,
Natalizumab,
Ocrelizumab,
Ofatumumab,
Ponesimod,
Rituximab,
Teriflunomide		[10] D01370 ,
D02802 (Name: Alemtuzumab),
D02994 ,
D03846 ,
D05218 ,
D06886 ,
D09314 ,
D10001 ,
D10172 ,
D11215 		[7] CD52,
DHODH,
ITGA4,
KEAP1,
MS4A1,
RRM1,
S1PR1 💬		[31] , Arrhythmogenic right ventricular cardiomyopathy, Biosynthesis of cofactors, Cell adhesion molecules, Chemical carcinogenesis - reactive oxygen species, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Glutathione metabolism, Hematopoietic cell lineage, Hepatocellular carcinoma, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, PI3K-Akt signaling pathway, Parkinson disease, Pathways in cancer, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Sphingolipid signaling pathway, Ubiquitin mediated proteolysis, Yersinia infection 💬[1] 13
20Transplant Conditioning with Mobilization and Alemtuzumab[1] Alemtuzumab[1] D02802 (Name: Alemtuzumab)[1] CD52 💬-[1] 65
21Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan[4] Alemtuzumab,
Fludarabine,
Melphalan,
Thiotepa		[4] D00369 ,
D00583 ,
D02802 (Name: Alemtuzumab),
D07966 		[2] CD52,
RRM1 💬		[7] , Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬[2] 65, 164